<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01104545</url>
  </required_header>
  <id_info>
    <org_study_id>3614-001</org_study_id>
    <secondary_id>MK-3614-001</secondary_id>
    <secondary_id>2010_525</secondary_id>
    <nct_id>NCT01104545</nct_id>
  </id_info>
  <brief_title>A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)</brief_title>
  <official_title>A Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-3614</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if MK-3614, given as single doses, is safe and well tolerated in
      healthy males and male participants with mild to moderate hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to three planned panels of either 8 healthy participants (Panels A and B) or 8
      participants with mild to moderate hypertension (Panel C) will be enrolled. In Panels A and
      B, 8 participants will alternately receive single rising doses of MK-3614 or placebo. All
      doses will be administered in the fasted state, except Panel A, Period 3 in which a standard
      high-fat breakfast provided approximately 30 minutes prior to dosing. Panel A will begin
      first. At least 3 days will elapse before participants in the alternate panel (Panel B) will
      receive the next higher dose. In Panel C, 8 mild to moderate hypertensive male participants
      will receive single rising doses of MK-8892 or placebo. For all panels, there will be at
      least 7 days washout between treatment periods for any given participant. Participants may
      only be enrolled in one panel of the study. All participants in periods of all panels (with
      exception of 0.25 mg fasted/fed periods) will be randomly assigned to either study drug or
      placebo, i.e., a participant could be assigned to receive study drug in one period and
      placebo in another. As per the protocol allocation plan, the same participants will receive
      0.25 mg MK-3612 in a fasted and fed state.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2008</start_date>
  <completion_date type="Actual">May 1, 2009</completion_date>
  <primary_completion_date type="Actual">May 1, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Reported 1 or More Adverse Event (AE) - Healthy Participants</measure>
    <time_frame>up to 7 days for each dose level</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized. AEs are reported by the dose taken at the time of the event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Were Discontinued From the Study Due to an AE - Healthy Participants</measure>
    <time_frame>up to 7 days for each dose level</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who were discontinued from the study due to an AE were summarized. AEs are reported by the dose taken at the time of the event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Report 1 or More Adverse Event (AE) - Hypertensive Participants</measure>
    <time_frame>up to 7 days for each dose level</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized. The percentage of participants that reported at least 1 AE was summarized. AEs are reported by the dose taken at the time of the event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Were Discontinued From the Study Due to an AE - Hypertensive Participants</measure>
    <time_frame>up to 7 days for each dose level</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who were discontinued from the study due to an AE were summarized. AEs are reported by the dose taken at the time of the event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of MK-3614 - Healthy Participants</measure>
    <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
    <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the AUC0-inf of MK-3614 in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of MK-3614- Healthy Participants</measure>
    <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
    <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Cmax of MK-3614 in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of MK-3614- Healthy Participants</measure>
    <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
    <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Tmax of MK-3614 in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) of MK-3614- Healthy Participants</measure>
    <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
    <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the t1/2 of MK-3614 in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of MK-3614 - Hypertensive Participants</measure>
    <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
    <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the AUC0-inf of MK-3614 in hypertensive participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of MK-3614- Hypertensive Participants</measure>
    <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
    <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Cmax of MK-3614 in hypertensive participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of MK-3614- Hypertensive Participants</measure>
    <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
    <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Tmax of MK-3614 in hypertensive participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) of MK-3614 of MK-3614- Hypertensive Participants</measure>
    <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
    <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the t1/2 of MK-3614 in hypertensive participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Heart Rate - Healthy Participants</measure>
    <time_frame>Baseline and 24 hours post-dose for each dose level</time_frame>
    <description>Heart rate measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Brachial Arterial Systolic Blood Pressure - Healthy Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Brachial arterial systolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Brachial Arterial Diastolic Blood Pressure - Healthy Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Brachial arterial diastolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Heart Rate - Hypertensive Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>HR measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of sequence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Brachial Arterial Systolic Blood Pressure - Hypertensive Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Brachial arterial systolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of sequence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Brachial Arterial Diastolic Blood Pressure - Hypertensive Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Brachial arterial diastolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of sequnce.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of 0.25 mg MK-3614 - Healthy Participants- Fasted Versus Fed</measure>
    <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
    <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the AUC0-inf of 0.25 mg MK-3614 in healthy participant when administered after an 8 hour fast and after a high-fat breakfest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of 0.25 mg MK-3614 - Healthy Participants- Fasted Versus Fed</measure>
    <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
    <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Cmax of 0.25 mg MK-3614 when administered after an 8 hour fast and after a high-fat breakfest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Augmentation Index (AIx) at 24 Hours Postdose - Healthy Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Augmentation index was measured at predose (baseline), and 1, 4, 8, 12, and 24 hours postdose by aplanation tonometry of radial artery. The change from baseline at 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Augmentation Index (AIx) at 24 Hours Postdose - Hypertensive Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Augmentation index was measured at predose (baseline), and 1, 4, 8, 12, and 24 hours postdose by aplanation tonometry of radial artery. The change from baseline at 24 hours postdose was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Bleeding Time at 24 Hours Postdose - Healthy Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Blood was to be drawn at predose (baseline) and 3 and 24 hours postdose and bleeding time was to be assessed using a Newborn Surgicutt device. Change in bleeding time from baseline at 24 hours postdose were to be summarized. Due to change in number of blood draws and total blood volume restrictions, bleeding time assessment was not performed as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Bleeding Time at 24 Hours Postdose- Hypertension Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Blood was to be drawn at predose (baseline) and 3 and 24 hours postdose and bleeding time was to be assessed using a Newborn Surgicutt device. Change in bleeding time from baseline at 24 hours postdose were to be summarized. Due to change in number of blood draws and total blood volume restrictions, bleeding time assessment was not performed as planned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Cyclic Guanosine Monophosphate (GMP) From Baseline at 24 Hours Postdose - Healthy Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Blood was drawn at predose (baseline) and 1, 4, 8, and 24 hours postdose. The change in cyclic GMP at 24 hours postdose was summarized. Due to change in number of blood draws and total blood volume restrictions, data for GMP were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized. Data for each specific dose were combined regardless of panel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Cyclic Guanosine Monophosphate (GMP) From Baseline at 24 Hours Postdose - Hypertension Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Blood was drawn at predose (baseline) and 1, 4, 8, and 24 hours postdose. The change in cyclic GMP at 24 hours postdose was summarized. Due to change in number of blood draws and total blood volume restrictions, data for GMP were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Platelet Aggregation at 24 Hours Postdose - Healthy Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Platelet aggregation induced by adenosine diphosphate (ADP) was measured at predose (baseline) and 3 and 24 hours postdose. Percent inhibition from baseline at 24 hours postdose was calculated. Due to change in number of blood draws and total blood volume restrictions, data for platelet aggregation were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized. Data for each specific dose were combined regardless of panel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Platelet Aggregation at 24 Hours Postdose - Hypertensive Participants</measure>
    <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
    <description>Platelet aggregation induced by adenosine diphosphate (ADP) was measured at predose (baseline) and 3 and 24 hours postdose. Percent inhibition from baseline at 24 hours postdose was calculated. Due to change in number of blood draws and total blood volume restrictions, data for platelet aggregation were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Panel A - Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants receive single oral dose of MK-3614 0.25 mg, 1.25 mg, 0.25 mg w/ food, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast except for Period 3. Period 3 dose was administered after the ingestion of a high-fat breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B - Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants receive single oral dose of MK-3614 0.5 mg. 0.75 mg, 0.25 mg twice a day (b.i.d.), 0.25 mg three times a day (t.i.d), or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C - Hypertensive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertensive participants receive single oral dose of MK-3614 0.75 mg. 0.5 mg. 0.75 mg, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing period. All doses were administered after an 8-hour fast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3614</intervention_name>
    <arm_group_label>Panel A - Healthy</arm_group_label>
    <arm_group_label>Panel B - Healthy</arm_group_label>
    <arm_group_label>Panel C - Hypertensive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <arm_group_label>Panel A - Healthy</arm_group_label>
    <arm_group_label>Panel B - Healthy</arm_group_label>
    <arm_group_label>Panel C - Hypertensive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants between 18 to 45 years of age; otherwise healthy participants
             between 18 to 55 years of age newly diagnosed with grade 1 or 2 hypertension

          -  Participant is in good general health

          -  Participant is a nonsmoker

        Exclusion Criteria:

          -  Participant has a history of stroke, seizure or major neurological disease

          -  Participant has functional disability that can interfere with rising from a sitting
             position to a standing position

          -  Participant has a family history of a bleeding or clotting disorder

          -  Participant has a history of cancer

          -  Participant is unable to refrain from or anticipates the use of any prescription or
             non-prescription medication during the study

          -  Participant consumes excessive amounts of alcohol or caffeine

          -  Participant has had major surgery, donated blood or participated in another
             investigational study in the past 4 weeks.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <results_first_submitted>September 13, 2018</results_first_submitted>
  <results_first_submitted_qc>June 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2019</results_first_posted>
  <last_update_submitted>June 24, 2019</last_update_submitted>
  <last_update_submitted_qc>June 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Three panels, each consisting of 8 participants (8 healthy young males in Panel A and Panel B; and 8 with mild-to-moderate hypertension in Panel C) were randomized to receive either MK-3614 or matching placebo in a 3:1 ratio, respectively, in up to 4 treatment periods in Panel A, Panel B and Panel C.</recruitment_details>
      <pre_assignment_details>Each period of each panel (with exception of 0.25 mg fasted/fed periods) will be re-randomized to receive either study drug or placebo, i.e., a participant could be assigned to receive study drug in one period and placebo in another. The same participants will receive 0.25 mg MK-3614 in a fasted and fed state.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Panel A - Healthy</title>
          <description>Healthy participants received a single oral dose of MK-3614 0.25 mg, 1.25 mg, 0.25 mg w/ food, 0.75 mg or matching placebo. There was at least a 7-day washout between the 4 dosing periods.</description>
        </group>
        <group group_id="P2">
          <title>Panel B - Healthy</title>
          <description>Healthy participants received a single oral dose of MK-3614 0.5 mg, 0.75 mg, 0.25 mg twice a day (b.i.d.), 0.25 mg three times a day (t.i.d), or matching placebo. There was at least a 7-day washout between the 4 dosing periods.</description>
        </group>
        <group group_id="P3">
          <title>Panel C - Hypertensive</title>
          <description>Hypertensive participants received a single oral dose of MK-3614 0.75 mg, 0.5 mg, 0.75 mg, 0.75 mg or matching placebo. There was at least a 7-day washout between the 4 dosing periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8">1 participant received 0.50 mg of MK-3614 or placebo in Periods 3 and 4 instead of planned 0.75 mg</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7">Participant discontinued after receiving 0.75 mg MK-3614 in Period 1</participants>
                <participants group_id="P3" count="6">Participants discontinued after receiving MK-3614 0.75 mg (Period 1)and placebo (Period 2)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Panel A - Healthy</title>
          <description>Healthy participants received a single oral dose of MK-3614 0.25 mg, 1.25 mg, 0.25 mg w/ food, 0.75 mg or matching placebo. There was at least a 7-day washout between the 4 dosing periods.</description>
        </group>
        <group group_id="B2">
          <title>Panel B - Healthy</title>
          <description>Healthy participants received a single oral dose of MK-3614 0.5 mg, 0.75 mg, 0.25 mg twice a day (b.i.d.), 0.25 mg three times a day (t.i.d), or matching placebo. There was at least a 7-day washout between the 4 dosing periods.</description>
        </group>
        <group group_id="B3">
          <title>Panel C - Hypertensive</title>
          <description>Hypertensive participants received a single oral dose of MK-3614 0.75 mg, 0.5 mg, 0.75 mg, 0.75 mg or matching placebo. There was at least a 7-day washout between the 4 dosing periods.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="6.8"/>
                    <measurement group_id="B2" value="33.4" spread="7.0"/>
                    <measurement group_id="B3" value="46.6" spread="9.4"/>
                    <measurement group_id="B4" value="36.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Reported 1 or More Adverse Event (AE) - Healthy Participants</title>
        <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized. AEs are reported by the dose taken at the time of the event.</description>
        <time_frame>up to 7 days for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>1.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 1.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg w/ Food MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after ingesting a high-fat breakfest</description>
          </group>
          <group group_id="O4">
            <title>0.75 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>Placebo Panel A</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O7">
            <title>0.75 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O8">
            <title>0.25 mg b.i.d. MK-3614 Panel B</title>
            <description>Participants received a single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O9">
            <title>0.25 mg t.i.d MK-3614 Panel B</title>
            <description>Participants received a single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
          <group group_id="O10">
            <title>Placebo Panel B</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Reported 1 or More Adverse Event (AE) - Healthy Participants</title>
          <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized. AEs are reported by the dose taken at the time of the event.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="80.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="66.7"/>
                    <measurement group_id="O7" value="66.7"/>
                    <measurement group_id="O8" value="20.0"/>
                    <measurement group_id="O9" value="60.0"/>
                    <measurement group_id="O10" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Were Discontinued From the Study Due to an AE - Healthy Participants</title>
        <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who were discontinued from the study due to an AE were summarized. AEs are reported by the dose taken at the time of the event.</description>
        <time_frame>up to 7 days for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>1.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 1.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg w/ Food MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after ingesting a high-fat breakfest</description>
          </group>
          <group group_id="O4">
            <title>0.75 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>Placebo Panel A</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O7">
            <title>0.75 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O8">
            <title>0.25 mg b.i.d. MK-3614 Panel B</title>
            <description>Participants received a single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O9">
            <title>0.25 mg t.i.d MK-3614 Panel B</title>
            <description>Participants received a single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
          <group group_id="O10">
            <title>Placebo Panel B</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Discontinued From the Study Due to an AE - Healthy Participants</title>
          <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who were discontinued from the study due to an AE were summarized. AEs are reported by the dose taken at the time of the event.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Report 1 or More Adverse Event (AE) - Hypertensive Participants</title>
        <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized. The percentage of participants that reported at least 1 AE was summarized. AEs are reported by the dose taken at the time of the event.</description>
        <time_frame>up to 7 days for each dose level</time_frame>
        <population>All participants in in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>Placebo Panel C</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Report 1 or More Adverse Event (AE) - Hypertensive Participants</title>
          <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized. The percentage of participants that reported at least 1 AE was summarized. AEs are reported by the dose taken at the time of the event.</description>
          <population>All participants in in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Were Discontinued From the Study Due to an AE - Hypertensive Participants</title>
        <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who were discontinued from the study due to an AE were summarized. AEs are reported by the dose taken at the time of the event.</description>
        <time_frame>up to 7 days for each dose level</time_frame>
        <population>All participants in in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>Placebo Panel C</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Discontinued From the Study Due to an AE - Hypertensive Participants</title>
          <description>An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants who were discontinued from the study due to an AE were summarized. AEs are reported by the dose taken at the time of the event.</description>
          <population>All participants in in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of MK-3614 - Healthy Participants</title>
        <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the AUC0-inf of MK-3614 in healthy participants.</description>
        <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>1.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 1.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg w/ Food MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after ingesting a high-fat breakfest</description>
          </group>
          <group group_id="O4">
            <title>0.75 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>0.5 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>0.75 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O7">
            <title>0.25 mg b.i.d. MK-3614 Panel B</title>
            <description>Participants received a single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O8">
            <title>0.25 mg t.i.d MK-3614 Panel B</title>
            <description>Participants received a single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of MK-3614 - Healthy Participants</title>
          <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the AUC0-inf of MK-3614 in healthy participants.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
          <units>nMh</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" spread="53.1"/>
                    <measurement group_id="O2" value="412.0" spread="96.4"/>
                    <measurement group_id="O3" value="83.8" spread="9.46"/>
                    <measurement group_id="O4" value="223.0" spread="83.1"/>
                    <measurement group_id="O5" value="173.0" spread="82.0"/>
                    <measurement group_id="O6" value="168.0" spread="27.7"/>
                    <measurement group_id="O7" value="NA" spread="NA">AUC0-inf not calculated for multiple dose arms</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">AUC0-inf not calculated for multiple dose arms</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of MK-3614- Healthy Participants</title>
        <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Cmax of MK-3614 in healthy participants.</description>
        <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>1.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 1.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg w/ Food MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after ingesting a high-fat breakfest</description>
          </group>
          <group group_id="O4">
            <title>0.75 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>0.5 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>0.75 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O7">
            <title>0.25 mg b.i.d. MK-3614 Panel B</title>
            <description>Participants received a single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O8">
            <title>0.25 mg t.i.d MK-3614 Panel B</title>
            <description>Participants received a single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of MK-3614- Healthy Participants</title>
          <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Cmax of MK-3614 in healthy participants.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="1.68"/>
                    <measurement group_id="O2" value="29.8" spread="5.20"/>
                    <measurement group_id="O3" value="3.6" spread="1.09"/>
                    <measurement group_id="O4" value="17.0" spread="4.48"/>
                    <measurement group_id="O5" value="11.5" spread="4.22"/>
                    <measurement group_id="O6" value="13.4" spread="2.24"/>
                    <measurement group_id="O7" value="5.1" spread="0.55"/>
                    <measurement group_id="O8" value="7.1" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Cmax (Tmax) of MK-3614- Healthy Participants</title>
        <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Tmax of MK-3614 in healthy participants.</description>
        <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>1.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 1.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg w/ Food MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after ingesting a high-fat breakfest</description>
          </group>
          <group group_id="O4">
            <title>0.75 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>0.5 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>0.75 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O7">
            <title>0.25 mg b.i.d. MK-3614 Panel B</title>
            <description>Participants received a single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O8">
            <title>0.25 mg t.i.d MK-3614 Panel B</title>
            <description>Participants received a single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) of MK-3614- Healthy Participants</title>
          <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Tmax of MK-3614 in healthy participants.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
          <units>hour (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="4.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="6.0" lower_limit="6.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="4.0" lower_limit="4.0" upper_limit="6.0"/>
                    <measurement group_id="O5" value="4.0" lower_limit="4.0" upper_limit="8.0"/>
                    <measurement group_id="O6" value="4.0" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O7" value="4.0" lower_limit="4.0" upper_limit="4.0"/>
                    <measurement group_id="O8" value="16.0" lower_limit="16.0" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life (t1/2) of MK-3614- Healthy Participants</title>
        <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the t1/2 of MK-3614 in healthy participants.</description>
        <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>1.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 1.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg w/ Food MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after ingesting a high-fat breakfest</description>
          </group>
          <group group_id="O4">
            <title>0.75 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>0.5 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>0.75 mg MK-3614 Panel B</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O7">
            <title>0.25 mg b.i.d. MK-3614 Panel B</title>
            <description>Participants received a single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O8">
            <title>0.25 mg t.i.d MK-3614 Panel B</title>
            <description>Participants received a single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) of MK-3614- Healthy Participants</title>
          <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the t1/2 of MK-3614 in healthy participants.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="4.5"/>
                    <measurement group_id="O2" value="10.1" spread="2.3"/>
                    <measurement group_id="O3" value="13.1" spread="1.2"/>
                    <measurement group_id="O4" value="9.1" spread="3.0"/>
                    <measurement group_id="O5" value="9.7" spread="3.6"/>
                    <measurement group_id="O6" value="9.5" spread="2.1"/>
                    <measurement group_id="O7" value="11.7" spread="4.1"/>
                    <measurement group_id="O8" value="14.7" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of MK-3614 - Hypertensive Participants</title>
        <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the AUC0-inf of MK-3614 in hypertensive participants</description>
        <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
        <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint. Data were summarized by dose taken and not by sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of MK-3614 - Hypertensive Participants</title>
          <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the AUC0-inf of MK-3614 in hypertensive participants</description>
          <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint. Data were summarized by dose taken and not by sequence.</population>
          <units>nMh</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.0" spread="52.0"/>
                    <measurement group_id="O2" value="134.0" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of MK-3614- Hypertensive Participants</title>
        <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Cmax of MK-3614 in hypertensive participants</description>
        <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
        <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint. Data were summarized by dose taken and not by sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of MK-3614- Hypertensive Participants</title>
          <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Cmax of MK-3614 in hypertensive participants</description>
          <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint. Data were summarized by dose taken and not by sequence.</population>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="3.88"/>
                    <measurement group_id="O2" value="10.9" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Cmax (Tmax) of MK-3614- Hypertensive Participants</title>
        <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Tmax of MK-3614 in hypertensive participants</description>
        <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
        <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint. Data were summarized by dose taken and not by sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) of MK-3614- Hypertensive Participants</title>
          <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Tmax of MK-3614 in hypertensive participants</description>
          <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint. Data were summarized by dose taken and not by sequence.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="4.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life (t1/2) of MK-3614 of MK-3614- Hypertensive Participants</title>
        <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the t1/2 of MK-3614 in hypertensive participants</description>
        <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
        <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint. Data were summarized by dose taken and not by sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) of MK-3614 of MK-3614- Hypertensive Participants</title>
          <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the t1/2 of MK-3614 in hypertensive participants</description>
          <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint. Data were summarized by dose taken and not by sequence.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="2.8"/>
                    <measurement group_id="O2" value="8.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Heart Rate - Healthy Participants</title>
        <description>Heart rate measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
        <time_frame>Baseline and 24 hours post-dose for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614</title>
            <description>Participants received single oral dose of 0.25 mg MK-3614 either after an 8 -hour fast or after a high-fat breakfast.</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg Twice a Day (b.i.d.) MK-3614</title>
            <description>Participants received single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg t.i.d MK-3614</title>
            <description>Participants received single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>1.25 mg MK-3614</title>
            <description>Participants received a single daily dose of 1.25 mg MK-3614</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate - Healthy Participants</title>
          <description>Heart rate measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>Beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="3.7"/>
                    <measurement group_id="O2" value="-0.6" spread="7.2"/>
                    <measurement group_id="O3" value="5.4" spread="7.2"/>
                    <measurement group_id="O4" value="2.5" spread="4.8"/>
                    <measurement group_id="O5" value="-0.3" spread="5.9"/>
                    <measurement group_id="O6" value="6.3" spread="11.8"/>
                    <measurement group_id="O7" value="3.8" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Brachial Arterial Systolic Blood Pressure - Healthy Participants</title>
        <description>Brachial arterial systolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614</title>
            <description>Participants received single oral dose of 0.25 mg MK-3614 either after an 8 -hour fast or after a high-fat breakfast.</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg Twice a Day (b.i.d.) MK-3614</title>
            <description>Participants received single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg t.i.d MK-3614</title>
            <description>Participants received single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>1.25 mg MK-3614</title>
            <description>Participants received a single daily dose of 1.25 mg MK-3614</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brachial Arterial Systolic Blood Pressure - Healthy Participants</title>
          <description>Brachial arterial systolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="4.8"/>
                    <measurement group_id="O2" value="2.4" spread="2.3"/>
                    <measurement group_id="O3" value="-2.6" spread="5.3"/>
                    <measurement group_id="O4" value="-1.0" spread="9.2"/>
                    <measurement group_id="O5" value="-3.1" spread="5.7"/>
                    <measurement group_id="O6" value="-3.0" spread="8.0"/>
                    <measurement group_id="O7" value="-0.2" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Brachial Arterial Diastolic Blood Pressure - Healthy Participants</title>
        <description>Brachial arterial diastolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614</title>
            <description>Participants received single oral dose of 0.25 mg MK-3614 either after an 8 -hour fast or after a high-fat breakfast.</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg Twice a Day (b.i.d.) MK-3614</title>
            <description>Participants received single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg t.i.d MK-3614</title>
            <description>Participants received single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>1.25 mg MK-3614</title>
            <description>Participants received a single daily dose of 1.25 mg MK-3614</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brachial Arterial Diastolic Blood Pressure - Healthy Participants</title>
          <description>Brachial arterial diastolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="3.1"/>
                    <measurement group_id="O2" value="0.8" spread="6.7"/>
                    <measurement group_id="O3" value="-2.8" spread="5.4"/>
                    <measurement group_id="O4" value="-1.0" spread="5.6"/>
                    <measurement group_id="O5" value="-1.8" spread="4.0"/>
                    <measurement group_id="O6" value="3.2" spread="6.0"/>
                    <measurement group_id="O7" value="-0.6" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Heart Rate - Hypertensive Participants</title>
        <description>HR measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of sequence.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>Placebo Panel C</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate - Hypertensive Participants</title>
          <description>HR measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of sequence.</description>
          <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="8.1"/>
                    <measurement group_id="O2" value="0.8" spread="10.7"/>
                    <measurement group_id="O3" value="-8.4" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Brachial Arterial Systolic Blood Pressure - Hypertensive Participants</title>
        <description>Brachial arterial systolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of sequence.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>Placebo Panel C</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brachial Arterial Systolic Blood Pressure - Hypertensive Participants</title>
          <description>Brachial arterial systolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of sequence.</description>
          <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="14.2"/>
                    <measurement group_id="O2" value="-10.0" spread="13.0"/>
                    <measurement group_id="O3" value="-18.1" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Brachial Arterial Diastolic Blood Pressure - Hypertensive Participants</title>
        <description>Brachial arterial diastolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of sequnce.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participant received single oral dose of 0.5 mg of MK-3614 after an 8 -hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>Placebo Panel C</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brachial Arterial Diastolic Blood Pressure - Hypertensive Participants</title>
          <description>Brachial arterial diastolic blood pressure measurements were obtained using a validated, semi-automated oscillometric device. The difference between the predose (baseline) measurement and the measurement 24 obtained 24 hours postdose was summarized. Data for each specific dose were combined regardless of sequnce.</description>
          <population>All participants in in Panel C who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="9.3"/>
                    <measurement group_id="O2" value="-4.4" spread="6.5"/>
                    <measurement group_id="O3" value="-9.1" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of 0.25 mg MK-3614 - Healthy Participants- Fasted Versus Fed</title>
        <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the AUC0-inf of 0.25 mg MK-3614 in healthy participant when administered after an 8 hour fast and after a high-fat breakfest.</description>
        <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
        <population>All participants in Panels A who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg w/ Food MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after ingesting a high-fat breakfest</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time-curve From Hour 0 to Infinity (AUC0-inf) of 0.25 mg MK-3614 - Healthy Participants- Fasted Versus Fed</title>
          <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the AUC0-inf of 0.25 mg MK-3614 in healthy participant when administered after an 8 hour fast and after a high-fat breakfest.</description>
          <population>All participants in Panels A who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
          <units>nMh</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" spread="53.1"/>
                    <measurement group_id="O2" value="83.8" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio (GMR)</param_type>
            <param_value>1.0</param_value>
            <estimate_desc>GMR = Fed/Fasted</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) of 0.25 mg MK-3614 - Healthy Participants- Fasted Versus Fed</title>
        <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Cmax of 0.25 mg MK-3614 when administered after an 8 hour fast and after a high-fat breakfest.</description>
        <time_frame>Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose for each dose level</time_frame>
        <population>All participants in Panel A who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg w/ Food MK-3614 Panel A</title>
            <description>Participants received a single oral dose of 0.25 mg MK-3614 after ingesting a high-fat breakfest</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of 0.25 mg MK-3614 - Healthy Participants- Fasted Versus Fed</title>
          <description>Blood samples taken at Predose, and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose of each dosing period to determine the Cmax of 0.25 mg MK-3614 when administered after an 8 hour fast and after a high-fat breakfest.</description>
          <population>All participants in Panel A who received at least 1 dose of study drug and who complied with the protocol sufficiently to ensure that these data will be likely to exhibit the effects of treatment, according to the underlying scientific model and had available data for the endpoint.</population>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" spread="1.68"/>
                    <measurement group_id="O2" value="3.56" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>0.73</param_value>
            <estimate_desc>GMR = Fed/fasted</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Augmentation Index (AIx) at 24 Hours Postdose - Healthy Participants</title>
        <description>Augmentation index was measured at predose (baseline), and 1, 4, 8, 12, and 24 hours postdose by aplanation tonometry of radial artery. The change from baseline at 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614</title>
            <description>Participants received single oral dose of 0.25 mg MK-3614 either after an 8 -hour fast or after a high-fat breakfast.</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg b.i.d. MK-3614</title>
            <description>Participants received single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg t.i.d MK-3614</title>
            <description>Participants received single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>1.25 mg MK-3614</title>
            <description>Participants received a single daily dose of 1.25 mg MK-3614</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Augmentation Index (AIx) at 24 Hours Postdose - Healthy Participants</title>
          <description>Augmentation index was measured at predose (baseline), and 1, 4, 8, 12, and 24 hours postdose by aplanation tonometry of radial artery. The change from baseline at 24 hours postdose was summarized. Data for each specific dose were combined regardless of panel.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="10.1"/>
                    <measurement group_id="O2" value="-5.2" spread="7.9"/>
                    <measurement group_id="O3" value="-0.8" spread="3.1"/>
                    <measurement group_id="O4" value="-1.8" spread="6.0"/>
                    <measurement group_id="O5" value="-3.0" spread="4.0"/>
                    <measurement group_id="O6" value="-1.5" spread="6.0"/>
                    <measurement group_id="O7" value="0.8" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Augmentation Index (AIx) at 24 Hours Postdose - Hypertensive Participants</title>
        <description>Augmentation index was measured at predose (baseline), and 1, 4, 8, 12, and 24 hours postdose by aplanation tonometry of radial artery. The change from baseline at 24 hours postdose was summarized.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>Placebo Panel C</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Augmentation Index (AIx) at 24 Hours Postdose - Hypertensive Participants</title>
          <description>Augmentation index was measured at predose (baseline), and 1, 4, 8, 12, and 24 hours postdose by aplanation tonometry of radial artery. The change from baseline at 24 hours postdose was summarized.</description>
          <population>All participants in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="6.4"/>
                    <measurement group_id="O2" value="-2.3" spread="4.9"/>
                    <measurement group_id="O3" value="1.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Bleeding Time at 24 Hours Postdose - Healthy Participants</title>
        <description>Blood was to be drawn at predose (baseline) and 3 and 24 hours postdose and bleeding time was to be assessed using a Newborn Surgicutt device. Change in bleeding time from baseline at 24 hours postdose were to be summarized. Due to change in number of blood draws and total blood volume restrictions, bleeding time assessment was not performed as planned.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614</title>
            <description>Participants received single oral dose of 0.25 mg MK-3614 either after an 8 -hour fast or after a high-fat breakfast.</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg b.i.d. MK-3614</title>
            <description>Participants received single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg t.i.d MK-3614</title>
            <description>Participants received single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>1.25 mg MK-3614</title>
            <description>Participants received a single daily dose of 1.25 mg MK-3614</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Bleeding Time at 24 Hours Postdose - Healthy Participants</title>
          <description>Blood was to be drawn at predose (baseline) and 3 and 24 hours postdose and bleeding time was to be assessed using a Newborn Surgicutt device. Change in bleeding time from baseline at 24 hours postdose were to be summarized. Due to change in number of blood draws and total blood volume restrictions, bleeding time assessment was not performed as planned.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Bleeding Time at 24 Hours Postdose- Hypertension Participants</title>
        <description>Blood was to be drawn at predose (baseline) and 3 and 24 hours postdose and bleeding time was to be assessed using a Newborn Surgicutt device. Change in bleeding time from baseline at 24 hours postdose were to be summarized. Due to change in number of blood draws and total blood volume restrictions, bleeding time assessment was not performed as planned.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>Placebo Panel C</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Bleeding Time at 24 Hours Postdose- Hypertension Participants</title>
          <description>Blood was to be drawn at predose (baseline) and 3 and 24 hours postdose and bleeding time was to be assessed using a Newborn Surgicutt device. Change in bleeding time from baseline at 24 hours postdose were to be summarized. Due to change in number of blood draws and total blood volume restrictions, bleeding time assessment was not performed as planned.</description>
          <population>All participants in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Cyclic Guanosine Monophosphate (GMP) From Baseline at 24 Hours Postdose - Healthy Participants</title>
        <description>Blood was drawn at predose (baseline) and 1, 4, 8, and 24 hours postdose. The change in cyclic GMP at 24 hours postdose was summarized. Due to change in number of blood draws and total blood volume restrictions, data for GMP were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized. Data for each specific dose were combined regardless of panel.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614</title>
            <description>Participants received single oral dose of 0.25 mg MK-3614 either after an 8 -hour fast or after a high-fat breakfast.</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg b.i.d. MK-3614</title>
            <description>Participants received single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg t.i.d MK-3614</title>
            <description>Participants received single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>1.25 mg MK-3614</title>
            <description>Participants received a single daily dose of 1.25 mg MK-3614</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Cyclic Guanosine Monophosphate (GMP) From Baseline at 24 Hours Postdose - Healthy Participants</title>
          <description>Blood was drawn at predose (baseline) and 1, 4, 8, and 24 hours postdose. The change in cyclic GMP at 24 hours postdose was summarized. Due to change in number of blood draws and total blood volume restrictions, data for GMP were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized. Data for each specific dose were combined regardless of panel.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.2" spread="0.1"/>
                    <measurement group_id="O5" value="0.0" spread="0.1"/>
                    <measurement group_id="O6" value="0.0" spread="0.0"/>
                    <measurement group_id="O7" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Cyclic Guanosine Monophosphate (GMP) From Baseline at 24 Hours Postdose - Hypertension Participants</title>
        <description>Blood was drawn at predose (baseline) and 1, 4, 8, and 24 hours postdose. The change in cyclic GMP at 24 hours postdose was summarized. Due to change in number of blood draws and total blood volume restrictions, data for GMP were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>Placebo Panel C</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Cyclic Guanosine Monophosphate (GMP) From Baseline at 24 Hours Postdose - Hypertension Participants</title>
          <description>Blood was drawn at predose (baseline) and 1, 4, 8, and 24 hours postdose. The change in cyclic GMP at 24 hours postdose was summarized. Due to change in number of blood draws and total blood volume restrictions, data for GMP were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized.</description>
          <population>All participants in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.2" spread="0.2"/>
                    <measurement group_id="O3" value="0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Platelet Aggregation at 24 Hours Postdose - Healthy Participants</title>
        <description>Platelet aggregation induced by adenosine diphosphate (ADP) was measured at predose (baseline) and 3 and 24 hours postdose. Percent inhibition from baseline at 24 hours postdose was calculated. Due to change in number of blood draws and total blood volume restrictions, data for platelet aggregation were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized. Data for each specific dose were combined regardless of panel.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.25 mg MK-3614</title>
            <description>Participants received single oral dose of 0.25 mg MK-3614 either after an 8 -hour fast or after a high-fat breakfast.</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg b.i.d. MK-3614</title>
            <description>Participants received single daily dose of 0.25 mg MK-3614 b.i.d.</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg t.i.d MK-3614</title>
            <description>Participants received single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
          </group>
          <group group_id="O4">
            <title>0.5 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O5">
            <title>0.75 mg MK-3614</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O6">
            <title>1.25 mg MK-3614</title>
            <description>Participants received a single daily dose of 1.25 mg MK-3614</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Platelet Aggregation at 24 Hours Postdose - Healthy Participants</title>
          <description>Platelet aggregation induced by adenosine diphosphate (ADP) was measured at predose (baseline) and 3 and 24 hours postdose. Percent inhibition from baseline at 24 hours postdose was calculated. Due to change in number of blood draws and total blood volume restrictions, data for platelet aggregation were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized. Data for each specific dose were combined regardless of panel.</description>
          <population>All participants in Panels A and B who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="-22.3" spread="26.3"/>
                    <measurement group_id="O7" value="-5.0" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Platelet Aggregation at 24 Hours Postdose - Hypertensive Participants</title>
        <description>Platelet aggregation induced by adenosine diphosphate (ADP) was measured at predose (baseline) and 3 and 24 hours postdose. Percent inhibition from baseline at 24 hours postdose was calculated. Due to change in number of blood draws and total blood volume restrictions, data for platelet aggregation were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized.</description>
        <time_frame>Baseline and 24 hours postdose for each dose level</time_frame>
        <population>All participants in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O2">
            <title>0.75 mg MK-3614 Panel C</title>
            <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
          </group>
          <group group_id="O3">
            <title>Placebo Panel C</title>
            <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Platelet Aggregation at 24 Hours Postdose - Hypertensive Participants</title>
          <description>Platelet aggregation induced by adenosine diphosphate (ADP) was measured at predose (baseline) and 3 and 24 hours postdose. Percent inhibition from baseline at 24 hours postdose was calculated. Due to change in number of blood draws and total blood volume restrictions, data for platelet aggregation were only collected for first 2 periods of each panel. Therefore only limited data were available and summarized.</description>
          <population>All participants in Panel C who received at least 1 dose of study drug and had available data for endpoint.</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-9.3" spread="12.9"/>
                    <measurement group_id="O3" value="-19.5" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 7 days postdose for each dose level (up to 15 weeks total)</time_frame>
      <desc>All participants that received at least 1 dose of study drug and had data available for endpoint.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.25 mg MK-3614 Panel A</title>
          <description>Participants received a single oral dose of 0.25 mg MK-3614 after an 8-hour fast</description>
        </group>
        <group group_id="E2">
          <title>1.25 mg MK-3614 Panel A</title>
          <description>Participants received a single oral dose of 1.25 mg MK-3614 after an 8-hour fast</description>
        </group>
        <group group_id="E3">
          <title>0.25 mg w/ Food MK-3614 Panel A</title>
          <description>Participants received a single oral dose of 0.25 mg MK-3614 after ingesting a high-fat breakfest</description>
        </group>
        <group group_id="E4">
          <title>0.75 mg MK-3614 Panel A</title>
          <description>Participant received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
        </group>
        <group group_id="E5">
          <title>Placebo Panel A</title>
          <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
        </group>
        <group group_id="E6">
          <title>0.5 mg MK-3614 Panel B</title>
          <description>Participants received a single oral dose of 0.50 mg MK-3614 after an 8-hour fast</description>
        </group>
        <group group_id="E7">
          <title>0.75 mg MK-3614 Panel B</title>
          <description>Participants received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
        </group>
        <group group_id="E8">
          <title>0.25 mg b.i.d. MK-3614 Panel B</title>
          <description>Participants received a single daily dose of 0.25 mg MK-3614 b.i.d.</description>
        </group>
        <group group_id="E9">
          <title>0.25 mg t.i.d MK-3614 Panel B</title>
          <description>Participants received a single daily oral dose of 0.25 mg MK-3614 t.i.d.</description>
        </group>
        <group group_id="E10">
          <title>Placebo Panel B</title>
          <description>Participants received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
        </group>
        <group group_id="E11">
          <title>0.75 mg MK-3614 Panel C</title>
          <description>Participant received a single oral dose of 0.75 mg MK-3614 after an 8-hour fast</description>
        </group>
        <group group_id="E12">
          <title>0.5 mg MK-3614 Panel C</title>
          <description>Participants received a single oral dose of 0.5 mg MK-3614 after an 8-hour fast</description>
        </group>
        <group group_id="E13">
          <title>Placebo Panel C</title>
          <description>Participant received a single oral dose of placebo for MK-3614 after an 8-hour fast</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood immunoglobulin E increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood pressure orthostatic decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="24" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="21" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Orthostatic heart rate response increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysstasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" events="6" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vibratory sense increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

